BS_42DY6WS7
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- age_years
- 4.425
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.370
- INTERFERON_ALPHA_RESPONSE+0.325
- ANDROGEN_RESPONSE+0.302
- BILE_ACID_METABOLISM+0.233
- ADIPOGENESIS+0.227
- INTERFERON_GAMMA_RESPONSE+0.212
- CHOLESTEROL_HOMEOSTASIS+0.202
- MYOGENESIS+0.201
- TGF_BETA_SIGNALING+0.174
- FATTY_ACID_METABOLISM+0.168
Top 10 suppressed
- E2F_TARGETS-0.526
- G2M_CHECKPOINT-0.468
- MYC_TARGETS_V1-0.386
- MYC_TARGETS_V2-0.378
- PANCREAS_BETA_CELLS-0.299
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.260
- MTORC1_SIGNALING-0.228
- UV_RESPONSE_UP-0.172
- UNFOLDED_PROTEIN_RESPONSE-0.161
- GLYCOLYSIS-0.156
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_5PV5N4HQ | pilocytic astrocytoma | — | 0.892 |
| 2 | BS_66ABA973 | pilocytic astrocytoma | — | 0.879 |
| 3 | BS_CTR5X93B | pilocytic astrocytoma | — | 0.864 |
| 4 | BS_3Q0GTSYH | pilocytic astrocytoma | — | 0.861 |
| 5 | BS_A13BMEF5 | low-grade glioma | — | 0.848 |
| 6 | BS_H3FE3TH9 | pilocytic astrocytoma | — | 0.847 |
| 7 | BS_9SJWWYQ4 | pilocytic astrocytoma | — | 0.846 |
| 8 | BS_GHNJ4CYC | low-grade glioma | — | 0.844 |
| 9 | BS_Y0PCBNJV | pilocytic astrocytoma | — | 0.841 |
| 10 | BS_JVA2NQFF | pilocytic astrocytoma | — | 0.819 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.325 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.302 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.233 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.227 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.212 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.202 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.201 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.174 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.168 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.160 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.154 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.148 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.138 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.136 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.131 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.122 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.118 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.116 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.108 | Temsirolimus | — uncovered |